Matthew Gubens, MD, MS
Associate Professor Thoracic Oncology
University of California, San Francisco
San Francisco, California

Leora Horn, MD, MSc, FRCPC
Associate Professor of Medicine
Clinical Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Karen L. Reckamp, MD, MS
Professor Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.

The faculty and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Faculty Disclosures

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Mersana Therapeutics, and Novartis and funds for research support paid to his institution from Merck and OncoMed.

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Xcovery and funds for research support from Boehringer Ingelheim and Xcovery.

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from Amgen, Astellas, Euclises, Takeda/Ariad, and Tesaro and funds for research support from AbbVie, ACEA, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Guardant Health, Loxo Oncology, Novartis, Pfizer, Seattle Genetics, Takeda/Ariad, and Xcovery.

Staff Disclosures

The activity planning staff listed below has no relevant financial relationships to disclose:
Timothy Quill, PhD; Megan Cartwright, PhD; Rachael M. Andrie, PhD; Kevin Obholz, PhD
Kimberly Bayer; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Rashmi Kumar, PhD; Heather Matt; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio, MS; Liz Rieder; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017)

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:

Donald Harting, ELS, CHCP, has disclosed that he has equity interest/stock options from Laboratory Corporation of America (LabCorp).

Katherine Pierce has disclosed that she has equity interest/stock options from Boston Scientific Corporation and Pfizer Inc.

The NCCN clinical information team listed below, who have reviewed content, have no relevant financial relationships to disclose:
Miranda Hughes, PhD

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.